Cancer Research The Future of Cancer Research: Science and Patient Impact  09 AM Call for Abstracts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 20, 1372-1382, October 1, 1960]
© 1960 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bogden, A. E.
Right arrow Articles by Aptekman, P. M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Bogden, A. E.
Right arrow Articles by Aptekman, P. M.

The R-1 Factor, a Histocompatibility Antigen in the Rat*

Arthur E. Bogden{dagger} and Paul M. Aptekman

( The Wistar Institute, Philadelphia 4, Pa.)

Studies of the humoral antibody response in rats of the random-bred Wistar strain, resistant to implantation of its "native" ascites tumor (AA), revealed a hemagglutinin that reacted with the erythrocytes of 90 per cent of Wistar strain rats.

The presence or absence of this hemagglutinogen (termed R-1 factor hemagglutinogen) in the host's tissues determined intraperitoneal AA tumor growth or rejection, respectively.

A second (weaker ?) histocompatibility factor was detected by subcutaneous implantation of AA ascites and appeared to be nonhemagglutinogenic.

Based upon a multiple allele hypothesis this study has indicated the existence of three alleles controlling the presence or absence of two possible histocompatibility antigens, R-1a (BC), R-1b (Bc), and R-1c (bc). The hemagglutinogen has been designated as B.

Several rat strains were screened for the R-1 hemagglutinogen (B). The inbred P.A. strain was 100 per cent R-1-positive, and the inbred Lewis strain was 100 per cent R-1-negative, indicating the homogeneity of inbred systems. Heterogeneity was indicated in the random-bred Wistar strain (90 per cent R-1 positive), and in the pen-bred Chocolate strain (88 per cent R-1-positive).

The anti-R-1 (anti-B) hemagglutinin appeared to be a "serum agglutinin" resembling the incomplete form of the human Rh antibody in that its avidity for the R-1-positive erythrocyte was markedly reduced in saline concentrations greater than that found normally in serum.

A cytotoxic antibody reactive against the R-1a AA tumor could be induced in R-1c rats by both normal and tumor tissues containing the R-1 hemagglutinogen.

The cytotoxic antibody in anti-R-1 sera was easily and completely absorbable by R-1-positive tumor cells but only partially by R-1-positive erythrocytes.

The parallelism between the activity of the R-1 antigens in the rat and the H-2 antigens in the mouse, and the relationship of the R-1 factor to certain blood groups in the rat, are discussed.

* This work was supported in part by a research grant from the National Cancer Institute of the National Institutes of Health, U.S. Public Health Service, and by a research grant from the Damon Runyon Fund, Inc.

{dagger} Present address: Division of Cancer Immunology, The Biochemical Research Foundation, Newark, Delaware.

Received 4/24/60.





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1960 by the American Association for Cancer Research.